【摘要】 目的探讨厄洛替尼治疗终末期(PS评分≥3分)非小细胞肺癌的疗效。方法终末期非小细胞肺癌患者47例,随机分为2组,治疗组25例接受厄洛替尼治疗,对照组22例不接受厄洛替尼治疗和其他放化疗,只接受营养支持、控制疼痛、缓解症状等治疗。观察2组的临床疗效、不良反应、生存期及预后影响因素。结果治疗组疾病控制率为72.0%(18/25),高于对照组的27.3%(6/22),差异有统计学意义(P<0.01);治疗组不良反应皮疹发生率84.0%(21/25),腹泻发生率40.0%(10/25),厌食发生率12.0%(3/25),对照组无不良反应。中位生存期治疗组92d,对照组61 d,差异有统计学意义(P<0.01)。Cox分析表明,性别、年龄、既往化疗次数和化疗方案对疗效影响不大,而病理分型、EGFR突变情况和吸烟史是疗效的影响因素(P<0.05)。结论厄洛替尼可延长终末期非小细胞肺癌患者的生存期,提高疾病控制率。更多还原

【Abstract】 Objective To investigate the effect of erlotinib in treatment of end-stage(PS score ≥3 points) nonsmall cell lung cancer.Methods 47 cases of end-stage non-small cell lung cancer patients were randomly divided into two groups,treatment group of 25 patients who received erlotinib treatment,the control group with 22 cases are not accepted erlotinib therapy and other chemotherapy,only accept nutritional support,control pain,relieve symptoms treatment.The clinical efficacy of the two groups,adverse reactions,survival and prognostic factors were observed.Results The disease control rate was 72.0%(18/25) in treatment group which is higher than 27.3%(6/22) in the control group,the difference was statistically significant(P <0.01);in treatment group,the incidence of rash reaction was 84.0%(21/25),the incidence of diarrhea was 40.0%(10/25),anorexia incidence was 12.0%(3/25),the control group had no adverse reactions.The median survival in the treatment group was 92 d,control group was 61 d(P < 0.01).Cox analysis showed that gender,age,number of previous chemotherapy and type of chemotherapy had little effect on the efficacy,and pathological type,EGFR mutation status and smoking history is curative factors(P <0.05).Conclusion Erlotinib prolongs survival of end-stage nonsmall cell lung cancer patients and improve disease control rate.更多还原